Peptide P7 inhibits the bFGF‑stimulated proliferation and invasion of SKOV3 cells

Chen,Qiong; Yang,Ziying; Chen,Xiangnan; Shu,Li; Qu,Wanglei

doi:10.3892/etm.2019.7309

Peptide P7 inhibits the bFGF‑stimulated proliferation and invasion of SKOV3 cells

Authors:
- Qiong Chen
- Ziying Yang
- Xiangnan Chen
- Li Shu
- Wanglei Qu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Department of Obstetrics and Gynecology, Shangrao People's Hospital, Shangrao, Jiangxi 334000, P.R. China, Department of Laboratory Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
Published online on: February 25, 2019 https://doi.org/10.3892/etm.2019.7309
Pages: 3003-3008
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Peptide P7 specifically binds with basic fibroblast growth factor (bFGF) to inhibit the proliferation and invasion of numerous types of cancer cell. However, this effect has remained to be demonstrated in ovarian cancer‑derived cell lines. In the present study, the protein P7 was used treat bFGF‑stimulated SKOV3 epithelial ovarian cancer cells to explore the therapeutic potential of P7. An MTT and a scratch wound assay were used to respectively evaluate the proliferation and migration of bFGF‑stimulated SKOV3 cells treated with P7. Reverse transcription‑quantitative polymerase chain reaction analysis was used to detect the gene expression of urokinase‑type plasminogen activator (uPA), as well as matrix metallopeptidase (MMP)‑2 and ‑9, which have a role in cell migration/invasion. The morphology and proliferation of SKOV3 cells were not significantly affected by different concentrations of P7. However, P7 had an obvious inhibitory effect on the proliferation and migration of bFGF‑stimulated SKOV3 cells. Treatment with P7 significantly lowered the gene expression of uPA, MMP‑2 and MMP‑9 compared with that in the control group. In conclusion, the present results suggested that P7, which, at least in part, acts through inhibition of bFGF, may have a potential therapeutic application in epithelial ovarian cancer.

View Figures

View References

1	Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J and Karlan BY: Ovarian cancer. Nat Rev Dis Primers. 2:160612016. View Article : Google Scholar : PubMed/NCBI
2	Koshiyama M, Matsumura N and Konishi I: Subtypes of ovarian cancer and ovarian cancer screening. Diagnostics. 7:E122017. View Article : Google Scholar : PubMed/NCBI
3	Gaya AM and Rustin GJ: Vascular disrupting agents: A new class of drug in cancer therapy. Clin Oncol. 17:277–290. 2005. View Article : Google Scholar
4	Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA and Ashour OM: Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies-A review. J Adv Res. 8:591–605. 2017. View Article : Google Scholar : PubMed/NCBI
5	Bielenberg DR and Zetter BR: The contribution of angiogenesis to the process of metastasis. Cancer J. 21:267–273. 2015. View Article : Google Scholar : PubMed/NCBI
6	Burger RA: Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol. 121:230–238. 2011. View Article : Google Scholar : PubMed/NCBI
7	Monk BJ, Minion LE and Coleman RL: Anti-angiogenic agents in ovarian cancer: Past, present, and future. Ann Oncol. 27 (Suppl):i33–i39. 2016. View Article : Google Scholar : PubMed/NCBI
8	Chase DM, Chaplin DJ and Monk BJ: The development and use of vascular targeted therapy in ovarian cancer. Gynecol Oncol. 145:393–406. 2017. View Article : Google Scholar : PubMed/NCBI
9	Fan L, Li W, Ying S, Shi L, Wang Z, Chen G, Ye H, Wu X, Wu J, Liang G and Li X: A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer. Tumour Biol. 36:7233–7241. 2015. View Article : Google Scholar : PubMed/NCBI
10	Luo W, Yu Y, Wang R, He D, Wang C, Zeng X, Chen X, Tan X, Huang T and Wu X: P7 peptides targeting bFGF sensitize colorectal cancer cells to CPT-11. Int J Mol Med. 33:194–200. 2014. View Article : Google Scholar : PubMed/NCBI
11	Yu Y, Gao S, Li Q, Wang C, Lai X, Chen X, Wang R, Di J, Li T, Wang W and Wu X: The FGF2-binding peptide P7 inhibits melanoma growth in vitro and in vivo. J Cancer Res Clin Oncol. 138:1321–1328. 2012. View Article : Google Scholar : PubMed/NCBI
12	Li Q, Gao S, Yu Y, Wang W, Chen X, Wang R, Li T, Wang C, Li X and Wu X: A novel bFGF antagonist peptide inhibits breast cancer cell growth. Mol Med Rep. 6:210–214. 2012.PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, et al: Effect of screening on ovarian cancer mortality: The prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. Jama. 305:2295–2303. 2011. View Article : Google Scholar : PubMed/NCBI
15	Collins T, Gray K, Bista M, Skinner M, Hardy C, Wang H, Mettetal JT and Harmer AR: Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension. Br J Pharmacol. 175:618–630. 2018. View Article : Google Scholar : PubMed/NCBI
16	Hayman SR, Leung N, Grande JP and Garovic VD: VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep. 14:285–294. 2012. View Article : Google Scholar : PubMed/NCBI
17	Arkenau HT, Brunetto AT, Barriuso J, Olmos D, Eaton D, de Bono J, Judson I and Kaye S: Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer. Oncology. 76:151–156. 2009. View Article : Google Scholar : PubMed/NCBI
18	Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ and Fowler JM: Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol. 102:134–139. 2006. View Article : Google Scholar : PubMed/NCBI
19	Crickard K, Gross JL, Crickard U, Yoonessi M, Lele S, Herblin WF and Eidsvoog K: Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol Oncol. 55:277–284. 1994. View Article : Google Scholar : PubMed/NCBI
20	Hill DS, Martin S, Armstrong JL, Flockhart R, Tonison JJ, Simpson DG, Birch-Machin MA, Redfern CP and Lovat PE: Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma. Clin Cancer Res. 15:1192–1198. 2009. View Article : Google Scholar : PubMed/NCBI
21	Wu X, Yan Q, Huang Y, Huang H, Su Z, Xiao J, Zeng Y, Wang Y, Nie C, Yang Y and Li X: Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity. J Cell Mol Med. 14:351–356. 2010. View Article : Google Scholar : PubMed/NCBI
22	Binder BR, Mihaly J and Prager GW: uPAR-uPA-PAI-1 interactions and signaling: A vascular biologist's view. Thromb Haemost. 97:336–342. 2007. View Article : Google Scholar : PubMed/NCBI
23	Torng PL, Mao TL, Chan WY, Huang SC and Lin CT: Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol. 92:559–567. 2004. View Article : Google Scholar : PubMed/NCBI
24	Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W and Lengyel E: Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 7:2396–2404. 2001.PubMed/NCBI